Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Caladrius Biosciences, Inc is a biotechnology business based in the US. Caladrius Biosciences shares (CLBS) are listed on the NASDAQ and all prices are listed in US Dollars. Caladrius Biosciences employs 27 staff and has a market cap (total outstanding shares value) of USD$65.2 million.
|Latest market close||USD$1.54|
|52-week range||USD$1.05 - USD$3.21|
|50-day moving average||USD$1.5415|
|200-day moving average||USD$1.8245|
|Wall St. target price||USD$6.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.8742|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||-1.91%|
|1 month (2020-12-23)||1.99%|
|3 months (2020-10-22)||-8.88%|
|6 months (2020-07-22)||-39.13%|
|1 year (2020-01-22)||-48.15%|
|2 years (2019-01-22)||-67.30%|
|3 years (2018-01-22)||4.23|
|5 years (2016-01-22)||143.48%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-31.86%|
|Return on equity TTM||-24.53%|
|Market capitalisation||USD$65.2 million|
TTM: trailing 12 months
There are currently 144,669 Caladrius Biosciences shares held short by investors – that's known as Caladrius Biosciences's "short interest". This figure is 11.3% up from 130,016 last month.
There are a few different ways that this level of interest in shorting Caladrius Biosciences shares can be evaluated.
Caladrius Biosciences's "short interest ratio" (SIR) is the quantity of Caladrius Biosciences shares currently shorted divided by the average quantity of Caladrius Biosciences shares traded daily (recently around 258337.5). Caladrius Biosciences's SIR currently stands at 0.56. In other words for every 100,000 Caladrius Biosciences shares traded daily on the market, roughly 560 shares are currently held short.
However Caladrius Biosciences's short interest can also be evaluated against the total number of Caladrius Biosciences shares, or, against the total number of tradable Caladrius Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Caladrius Biosciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Caladrius Biosciences shares in existence, roughly 10 shares are currently held short) or 0.0081% of the tradable shares (for every 100,000 tradable Caladrius Biosciences shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Caladrius Biosciences.
Find out more about how you can short Caladrius Biosciences stock.
We're not expecting Caladrius Biosciences to pay a dividend over the next 12 months.
Caladrius Biosciences's shares were split on a 1:10 basis on 28 July 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Caladrius Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Caladrius Biosciences shares which in turn could have impacted Caladrius Biosciences's share price.
Over the last 12 months, Caladrius Biosciences's shares have ranged in value from as little as $1.05 up to $3.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caladrius Biosciences's is 1.5536. This would suggest that Caladrius Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.